RBC Capital Reiterates Outperform Rating for Ascendis Pharma (NASDAQ: ASND) following strong Q2 2026 results. Aug 14, 2026 Market News FMPRBC Capital Reiterates Outperform Rating for Ascendis Pharma (NASDAQ: ASND) Foll... * RBC Capital maintains an Outperform rating for Ascendis Pharma (NASDAQ: ASND), raising its price target to $290.00. * The biopharmaceutical company reported robust Q2 2026 financial performance, with total revenue reaching EUR 339 million, driven by significant product sales growth. * Ascendis Pharma achieved a net profit of EUR 207 million and ended the quarter with a strong cash position of EUR 812 million. On August 14, 2026, RBC Capital reiterates its Outperform rating for Ascendis Pharma, a biopharmaceutical company that develops therapies using its TransCon technology. The bank raises its price target on the stock to $290.00 from $280.00. At the time of the rating, Ascendis Pharma's stock price is $246.23. This positive analyst view follows the company's strong financial performance. For its second quarter of 2026, Ascendis Pharma reports total revenue of EUR 339 million. As highlighted by MarketBeat, this includes EUR 315 million in product revenue, which more than doubles from the prior-year period due to increasing demand for its therapies. The revenue growth is driven by its three main products. YORVIPATH(R) generates €252 million, SKYTROFA(R) brings in €55 million, and YUVIWEL(R) contributes €8 million. According to a GlobeNewsWire report, the company also sees strong patient enrollment for YUVIWEL(R), with over 220 unique patients in the U.S. through July. The company reports a net profit of EUR 207 million for the quarter. Its operating profit stands at EUR 220 million, which is significantly helped by EUR 158 million in other income. This extra income comes from the sale of a priority review voucher, a coupon that can be sold to other companies for a faster FDA review. Ascendis Pharma ends the quarter with a strong cash position of EUR 812 million. This is after using EUR 56 million for its share-repurchase program, where a company buys back its own stock from the market. The company also reports it has settled all of its convertible notes, a type of debt. Market news and analyst rating coverage Gordon Thompson covers analyst rating changes, price-target updates, and company news for the FMP blog. His work focuses on summarizing the latest broker actions and market developments into accessible, data-driven updates for investors and analysts. Financial data for every need. Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions - all accessible via API. Stock Screener 2017-2026 (C) FMP

Ascendis Pharma (ASND):10 most profitable growth stocks to buy. Published on june 9, 2026 at 7:22 pm by maham fatima in news. Ascendis Pharma (NASDAQ:ASND) is one of the most profitable growth stocks to buy. On May 7, Ascendis Pharma reported strong financial results for Q1 2026, reaching a total revenue of €247 million. This growth was primarily driven by YORVIPATH, which generated €197 million, alongside €44 million from SKYTROFA. Additionally, the company announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $187.5 million, further strengthening its financial position. The company is experiencing robust commercial momentum, highlighted by over 1,000 new US patient enrollments for YORVIPATH and more than 60 enrollments for YUVIWEL following its early April launch. Ascendis is also advancing its clinical pipeline, including positive results from the COACH combination therapy trial, while making the strategic decision to discontinue internal oncology development to better align with its long-term focus. Operational updates for the quarter include a transition to trading ordinary shares on the Nasdaq Global Select Market and the full redemption of its 2028 convertible notes. With a net profit of €629 million and cash reserves of €573 million as of March 31, Ascendis Pharma (NASDAQ:ASND) continues to solidify its role as a leading global biopharmaceutical firm. Ascendis Pharma (NASDAQ:ASND) develops TransCon-based therapies for unmet medical needs. While we acknowledge the risk and potential of ASND as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ASND and that has 10,000% upside potential, check out our report about the cheapest AI stock.

Ascendis to showcase advances in treatment of rare endocrine diseases at ENDO 2026. COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) - Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026. "As a leader in rare endocrine diseases, we are committed to sharing comprehensive clinical trial results in peer-reviewed forums that reinforce the transformative potential of our innovative therapies," said Aimee Shu, M.D., Executive Vice President, Chief Medical Officer at Ascendis Pharma. "This year at ENDO, DPEX Network look forward to showcasing the long-term safety and efficacy of TransCon PTH, demonstrated through multiple clinical trials, as well as data demonstrating the long-term... Third-Party Content Disclaimer Content displayed on this platform may include news articles, reports, and other materials aggregated from publicly available third-party sources through automated tools. Such content is not created, written, commissioned, or edited by Straits Interactive Pte Ltd or the Data Protection Excellence (DPEX) Network. While DPEX Network take reasonable steps to ensure responsible publication, DPEX Network do not independently verify all third-party information and make no representations as to its accuracy, completeness, or reliability. The views, findings, and statements expressed in third-party content belong solely to the original source and do not reflect the views of Straits Interactive Pte Ltd or the DPEX Network. If you believe any content is inaccurate, infringing, or should be removed, please contact DPEX Network at [email protected]. DPEX Network will review the matter and, where appropriate, take action in accordance with its internal policies.